One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 2) by Azuma Hazuki on Sunday April 15 2018, @02:35PM (2 children)
This is why, as I have been saying since junior year of high school after the economics primer, we should not let "the market" rule when it comes to something with such inelastic demand. It's a hostage situation, literally "your money or your life," and in some cases they want both. When even Uzzard gets to the point where he's proposing government intervention, regulation, which he called one of the world's great evils not a week ago on this very forum, what does THAT say?
Oh Mr. Vim, where aaaarrreeee youuuuu...? You're already going to Hell, but I'd love to see you stamp your own passport there with your argument about why it's perfectly fine for this to happen.
I am "that girl" your mother warned you about...
(Score: 0) by Anonymous Coward on Sunday April 15 2018, @05:17PM (1 child)
Here. [soylentnews.org]
(Score: 0) by Anonymous Coward on Monday April 16 2018, @12:24AM
Well, that's slightly better than just reposting the who damned comment again and again and again.